Eosinophil-rich linear IgA bullous dermatosis; This literature-non-study case was reported in a literature article and describes the occurrence of LINEAR IGA DISEASE (Eosinophil-rich linear IgA bullous dermatosis) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.   LITERATURE REFERENCE:      No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced LINEAR IGA DISEASE (Eosinophil-rich linear IgA bullous dermatosis) (seriousness criterion medically significant). The patient was treated with DAPSONE (DAPSONE COX) at an unspecified dose and frequency. At the time of the report, LINEAR IGA DISEASE (Eosinophil-rich linear IgA bullous dermatosis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Biopsy: showing subepidermal blister with numerous eosinophils so, initially diagnosed with bullous pemphigoid. On an unknown date, Immunology test: shows linear IgA and IgM deposition along the basement membrane zone with no immunoreactivity for C3 or IgG and (Positive) for IgA basement membrane zone antibody.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was not provided.  The patient went to emergency department with a 3-week history of a pruritic blistering rash characterized by fluid-filled bullae and multiple annular and polycyclic plaques.   However, based on immunofluorescence studies the patient was subsequently diagnosed with eosinophil-rich linear IgA bullous disease (LABD).  The patient was on dapsone therapy with resolution of the lesions at 3-month follow-up.  Author concluded that the case illustrates the growing number of autoimmune blistering adverse cutaneous reactions from vaccination. Company comment-This literature non-study case concerns a 66-year-old male patient with no medical history reported, who experienced unexpected, serious (medically significant) event of Linear IgA disease (Reported as Eosinophil-rich linear IgA bullous dermatosis) after booster dose of mRNA-1273 vaccine in covid -19 vaccination series. Latency cannot be assessed since vaccination date nor event onset date was disclosed. Patient presented to the emergency department with a 3- week history of a pruritic blistering rash characterized by fluid-filled bullae and multiple annular and polycyclic plaques. He was initially diagnosed with bullous pemphigoid based on a biopsy showing a subepidermal blister with numerous eosinophils. However, direct immunofluorescence studies showed linear IgA and IgM deposition along the basement membrane zone with no immunoreactivity for C3 or IgG. Additionally, indirect immunofluorescence was positive for IgA basement membrane zone antibody. He was subsequently diagnosed with linear IgA bullous dermatosis (LABD) and initiated on dapsone therapy with resolution of his lesions at 3-month follow-up. This case illustrates the growing number of autoimmune blistering adverse cutaneous reactions from vaccination. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This literature non-study case concerns a 66-year-old male patient with no medical history reported, who experienced unexpected, serious (medically significant) event of Linear IgA disease (Reported as Eosinophil-rich linear IgA bullous dermatosis) after booster dose of mRNA-1273 vaccine in covid -19 vaccination series. Latency cannot be assessed since vaccination date nor event onset date was disclosed. Patient presented to the emergency department with a 3- week history of a pruritic blistering rash characterized by fluid-filled bullae and multiple annular and polycyclic plaques. He was initially diagnosed with bullous pemphigoid based on a biopsy showing a subepidermal blister with numerous eosinophils. However, direct immunofluorescence studies showed linear IgA and IgM deposition along the basement membrane zone with no immunoreactivity for C3 or IgG. Additionally, indirect immunofluorescence was positive for IgA basement membrane zone antibody. He was subsequently diagnosed with linear IgA bullous dermatosis (LABD) and initiated on dapsone therapy with resolution of his lesions at 3-month follow-up. This case illustrates the growing number of autoimmune blistering adverse cutaneous reactions from vaccination. The benefit-risk relationship of mRNA-1273 is not affected by this report.